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FOREWORD FROM THE EDITORS 
 In this issue of the Marquette Intellectual Property Law Review (IPLR), 
we have decided to experiment with some new concepts.  First, this issue is 
thematic, with a majority of articles and comments focusing on Pharmaceutical 
Development and Healthcare Innovation.  We felt that having an occasional 
thematic issue would be of value for readers with interest in a topical area, and 
also increase the overall impact of legal scholarship in the field, towards the 
goal of furthering public policy discussions.  That brings us to our second 
innovation, which is something we refer to as our Intellectual Property Policy 
Forum.  The purpose of this section, which is on the pages that follow, is to 
solicit forward-looking views on the topical issue, from thought leaders in the 
field.  To this end, we have identified an impressive array of nine leading 
figures in the area of Pharmaceutical Development and Healthcare Innovation.  
Their views and commentary give a view to where this field may be headed, 
and also gives a broader perspective to the legal scholarship contained in this 
topical issue.  Finally, to personalize this public policy and legal dialog, we 
have provided brief biographical information and pictures of our various 
contributors. 
 On behalf of the editorial board and staff of the Marquette IPLR, we 
hope you enjoy—and continue yourself—this dialog at the interface of law and 
public policy, on the topic of Pharmaceutical Development and Healthcare 
Innovation. 
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